China Lung Cancer Screening Market to Witness Strong Expansion, Says Persistence Market Research

Lung cancer remains one of the most deadly cancers worldwide, with China being no exception. With more than 700,000 deaths attributed to the disease annually, lung cancer represents a significant public health issue in the country. The early detection of lung cancer can dramatically improve survival rates, which has led to a rapid development of screening programs across the nation. The China lung cancer screening market is expected to see substantial growth, with an estimated market value reaching US$ 1,295.5 million by 2032 from US$ 616.2 million in 2025. The market is projected to grow at a compound annual growth rate (CAGR) of 11.2% during the forecast period from 2025 to 2032.

In China, lung cancer is predominantly diagnosed at advanced stages, which limits the effectiveness of treatment. This issue has spurred national efforts to implement widespread screening programs. Low-Dose Computed Tomography (LDCT) has emerged as the leading diagnostic tool, offering a non-invasive and highly sensitive method for detecting early-stage lung cancers, especially in high-risk populations. The adoption of LDCT as part of public health initiatives, especially for smokers and individuals exposed to environmental risk factors like air pollution, has been critical in shifting the paradigm towards early-stage diagnosis.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35427

Market Statistics, Key Growth Drivers, and Leading Segments

As mentioned, the China lung cancer screening market is set to grow at a robust pace, primarily driven by both government initiatives and technological advancements in diagnostic tools. The rise in lung cancer incidence, particularly among non-smokers due to exposure to pollution and indoor cooking fumes, has intensified the urgency for effective screening programs. The adoption of LDCT technology is set to dominate the market, accounting for 71.4% of the total market share by 2025. This technology has proven to be highly effective at detecting early-stage lung cancers, offering hope for improved survival rates and better patient outcomes.

The leading geographical region for lung cancer screening in China remains Shandong, where the incidence of lung cancer is particularly high. The province has shown consistent growth in screening uptake, bolstered by strong government-backed initiatives and local health programs. The province's high smoking rates and significant exposure to environmental risk factors, such as industrial emissions, make it a prime area for increased screening efforts.

Key Highlights from the Report

• Government-backed LDCT programs are propelling lung cancer early detection efforts in China.
• LDCT is expected to hold a significant market share, reaching 71.4% in 2025.
• NSCLC, specifically adenocarcinoma, is the predominant cancer type in China, forming 82.4% of lung cancer cases.
• AI integration into screening processes is boosting detection rates and reducing diagnostic uncertainty.
• Shandong province is witnessing a steady growth trajectory in lung cancer screening uptake.
• The market is projected to grow at a CAGR of 11.2% from 2025 to 2032, reaching US$ 1,295.5 million.

Market Segmentation

The China lung cancer screening market is segmented by product type, cancer type, and diagnostic method. Among diagnostic methods, Low-Dose Computed Tomography (LDCT) is expected to remain the dominant screening tool, accounting for the majority of the market share in the coming years. LDCT has the ability to detect smaller lesions, improving early detection rates and survival outcomes. However, chest X-rays (CXR) still play an important role in the overall diagnostic landscape, particularly in more affordable or rural settings, where access to LDCT may be limited.

In terms of cancer type, Non-Small Cell Lung Cancer (NSCLC) is the leading category, projected to account for 82.4% of the market by 2025. The increase in adenocarcinoma-a subtype of NSCLC that is largely attributed to air pollution and indoor cooking fumes-is the primary driver for this trend. Conversely, Small Cell Lung Cancer (SCLC) is expected to show a moderate increase in prevalence due to high smoking rates in certain regions.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/china-lung-cancer-screening-market.asp

Regional Insights
Shandong Lung Cancer Screening Market Trends

Shandong Province, known for its elevated lung cancer mortality rates, is witnessing a significant push toward improving early detection through LDCT. The province has adopted national guidelines for LDCT screening for high-risk populations, including those aged between 50 and 75 years, with a history of smoking or exposure to environmental pollutants. The government's strong push and local health policies are expected to enhance screening uptake and contribute to the overall growth of the market.

Sichuan Lung Cancer Screening Market Trends

In contrast, Sichuan Province faces challenges related to uneven access to healthcare facilities, particularly in rural and minority areas. Despite this, more than 95% of high-risk individuals in the province have access to LDCT screening within 60 minutes. However, participation remains lower than expected, with only 34.7% of high-risk adults completing their annual LDCT scans. Improving awareness and addressing logistical challenges could boost participation and lead to better outcomes in the future.

Market Drivers
Government Initiatives and Funding

The primary driver behind the growth of the lung cancer screening market in China is the government's active involvement in supporting early detection initiatives. Policies such as the National Lung Cancer Screening (NLCS) program, which includes the use of LDCT, have been implemented across various provinces. Regulatory bodies are working on developing guidelines, funding mechanisms, and technological support to expand these programs. The national government has also incorporated lung cancer screening into public health insurance coverage, making it more accessible to individuals from diverse socioeconomic backgrounds.

Increasing Incidence of Lung Cancer

The rapidly increasing incidence of lung cancer in China is another major factor driving the growth of the screening market. Studies have shown that lung cancer is becoming more prevalent among non-smokers, particularly due to the widespread issue of air pollution. Adenocarcinoma, the most common type of lung cancer, has seen a rise in incidence, further highlighting the need for routine screening to catch these cancers at an early, treatable stage.

Market Restraints
Low Uptake and Participation in Screening Programs

Despite the availability of free LDCT screening in certain regions, the uptake remains low. A study conducted between 2013 and 2019 revealed that of 55,428 individuals invited to participate in a Henan-based screening program, only 22,260 individuals completed the scan. Contributing factors include concerns over out-of-pocket costs, distrust in healthcare institutions, and limited health literacy, especially in rural areas.

High False-Positive Rates

Another key restraint is the high false-positive rate associated with LDCT screening. In large-scale national cohorts, the false-positive rate for lung cancer diagnoses has been over 68%, leading to unnecessary additional imaging, biopsies, and treatment. This high rate of false positives leads to anxiety among participants and strains healthcare resources, ultimately discouraging people from undergoing subsequent screenings.

Market Opportunities
Artificial Intelligence Integration

One of the most promising opportunities in the China lung cancer screening market is the integration of Artificial Intelligence (AI) into the screening process. AI-powered systems have demonstrated improved detection rates, including the ability to detect nodules with high sensitivity and specificity. AI-assisted detection has been found to outperform traditional methods in terms of accuracy, making it a promising tool for enhancing screening programs and reducing radiologist burden.

Expansion of Mobile and Telemedicine Solutions

With regional disparities in healthcare access, especially in rural areas, mobile and tele-radiology platforms present an exciting opportunity for expanding lung cancer screening services. These solutions could improve access to screening, offering more flexible and cost-effective options for individuals living in underserved regions. Furthermore, mobile CT units and other diagnostic tools are being deployed to overcome geographical barriers, ensuring that all high-risk individuals can benefit from early detection.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35427

Reasons to Buy the Report

• Comprehensive analysis of market trends and growth drivers in the China lung cancer screening market.
• Detailed market segmentation, including insights into diagnostic tools and cancer types.
• Overview of the competitive landscape and profiles of leading companies operating in the market.
• In-depth exploration of regional trends, particularly in Shandong, Sichuan, and Jiangsu.
• Valuable insights into emerging opportunities such as AI integration and mobile solutions for screening.

Frequently Asked Questions (FAQs)

• How Big is the China Lung Cancer Screening Market?
• Who are the Key Players in the Global Market for China Lung Cancer Screening?
• What is the Projected Growth Rate of the China Lung Cancer Screening Market?
• What is the Market Forecast for the China Lung Cancer Screening Market for 2032?
• Which Region is Estimated to Dominate the China Lung Cancer Screening Industry through the Forecast Period?

Company Insights

Key players operating in the China lung cancer screening market include:

• Biodesix
• GE HealthCare
• DELFI Diagnostics, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• CANON MEDICAL SYSTEMS CORPORATION
• Siemens Healthineers AG
• Medtronic plc
• Koninklijke Philips N.V.
• Freenome Holdings, Inc.
• Shanghai United Imaging Healthcare Co., LTD.

Recent Developments

In April 2025, researchers from the Guangzhou Institute of Respiratory Disease found that LDCT screening effectively detected lung cancer in non-smokers at comparable rates to smokers.

In January 2025, a study at Sichuan University revealed that only 23.88% of urban residents in Sichuan had sufficient awareness about lung cancer, underscoring the need for enhanced educational initiatives.

The China lung cancer screening market is poised for significant growth, driven by governmental initiatives, technological advancements, and a rising public demand for early detection services. With increasing awareness, AI integration, and expanding coverage, the landscape is expected to evolve, bringing better outcomes for individuals at risk of lung cancer.

Read More Related Reports:

Next Generation Iv Infusion Pumps Market https://www.persistencemarketresearch.com/market-research/next-generation-iv-infusion-pumps-market.asp
Ngs Based Diagnostics Market https://www.persistencemarketresearch.com/market-research/ngs-based-diagnostics-market.asp
Occupational Medicine Market https://www.persistencemarketresearch.com/market-research/occupational-medicine-market.asp
North America Synthetic Opioids Market https://www.persistencemarketresearch.com/market-research/north-america-synthetic-opioids-market.asp
Healthcare Quality And Safety Reporting System Market https://www.persistencemarketresearch.com/market-research/healthcare-quality-and-safety-reporting-system-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.